Addus HomeCare Corporation $ADUS Holdings Decreased by Summit Creek Advisors LLC

Summit Creek Advisors LLC trimmed its position in Addus HomeCare Corporation (NASDAQ:ADUS) by 15.7% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 71,750 shares of the company’s stock after selling 13,368 shares during the quarter. Addus HomeCare makes up 3.2% of Summit Creek Advisors LLC’s portfolio, making the stock its 2nd biggest position. Summit Creek Advisors LLC’s holdings in Addus HomeCare were worth $7,931,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Addus HomeCare during the second quarter valued at $344,153,000. Dimensional Fund Advisors LP lifted its stake in Addus HomeCare by 11.8% in the first quarter. Dimensional Fund Advisors LP now owns 744,127 shares of the company’s stock worth $69,689,000 after acquiring an additional 78,415 shares during the period. Bank of America Corp DE purchased a new stake in Addus HomeCare in the second quarter worth about $35,527,000. TimesSquare Capital Management LLC bought a new position in Addus HomeCare during the 2nd quarter worth about $31,502,000. Finally, Punch & Associates Investment Management Inc. bought a new position in Addus HomeCare during the 2nd quarter worth about $20,911,000. Institutional investors own 95.35% of the company’s stock.

Key Headlines Impacting Addus HomeCare

Here are the key news stories impacting Addus HomeCare this week:

• Positive Sentiment: UBS raised its price target to $160 from $145 and maintained a Buy rating; TD Cowen lifted its target to $145 from $131 and also maintained a Buy rating. UBS price-target report TD Cowen price-target report
• Positive Sentiment: ADUS recently reached a 52-week high. Its latest quarterly results included earnings per share of $1.83, ahead of the $1.79 consensus, while revenue increased 7% year over year. Addus hits a 12-month high
• Positive Sentiment: The company said it expects to close its AccentCare acquisition in the first quarter of 2027 and anticipates a full-year adjusted EBITDA margin around 13%; the deal may offer a growth opportunity, though execution remains ahead. AccentCare update
• Neutral Sentiment: Recent Zacks pieces discuss ADUS’s momentum and value-investing appeal, but the available summaries do not provide specific ratings or new estimates. Zacks momentum article Zacks value article
• Negative Sentiment: Quarterly revenue of $387.74 million was slightly below analysts’ $388.72 million estimate, tempering the otherwise positive earnings beat. Q3 earnings call highlights

Addus HomeCare Price Performance

NASDAQ ADUS opened at $124.31 on Friday. The firm’s fifty day simple moving average is $117.60 and its two-hundred day simple moving average is $106.88. The firm has a market capitalization of $2.32 billion, a P/E ratio of 20.72, a P/E/G ratio of 1.65 and a beta of 0.75. The company has a current ratio of 1.64, a quick ratio of 1.69 and a debt-to-equity ratio of 0.02. Addus HomeCare Corporation has a 12-month low of $87.95 and a 12-month high of $131.59.

Addus HomeCare (NASDAQ:ADUS) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.79 by $0.04. The firm had revenue of $387.74 million during the quarter, compared to analyst estimates of $388.72 million. Addus HomeCare had a return on equity of 10.22% and a net margin of 7.39%. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.56 EPS. Analysts forecast that Addus HomeCare Corporation will post 6.34 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Truist Financial raised their target price on shares of Addus HomeCare from $135.00 to $148.00 and gave the company a “buy” rating in a research report on Thursday. Barclays upped their price target on shares of Addus HomeCare from $96.00 to $101.00 and gave the stock an “underweight” rating in a research report on Wednesday. UBS Group increased their price objective on shares of Addus HomeCare from $145.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday. Royal Bank Of Canada lifted their price objective on shares of Addus HomeCare from $130.00 to $134.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings raised shares of Addus HomeCare from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $134.70.

Addus HomeCare Company Profile

Addus HomeCare Inc (NASDAQ: ADUS) provides in-home personal care, hospice and home health services to older adults, people with disabilities and other individuals who need assistance with daily living or medical care. Its services are designed to help clients remain safely and independently in their homes while supporting families and caregivers.

The company’s personal care services include assistance with bathing, dressing, grooming, meal preparation, housekeeping and other activities of daily living.